Floatz logo

AZD1775

Myelodysplastic Syndrome With Isolated Del(5q)

Mayo ClinicPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myelodysplastic Syndrome With Isolated Del(5q) cohort.

Asset / SponsorPhaseRating
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
Mayo Clinic
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 3BB

View all 15 →

Same molecule, other indications

AZD1775 is also rated in:

refractory malignant neoplasmDormant
B
Indicative ·
62 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
60 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →